Novartis delivers German Biotech’s 12th Antibody to Clinics

04/07/2016 - 2 minutes

MorphoSys keeps up its impressive productivity in feeding pipelines. Its 12th antibody in its Novartis collaboration has just reached clinical development.

morphosys hucal ylanthia antibody discoveryAfter presenting results for two of its wholly-owned candidates at ASCO 2016 (you can get an insider look into ASCO from the team), MorphoSys is receiving good news on the collaborations’ front.

One of the candidates it initially developed will start a Novartis-sponsored Phase I trials for prevention of thrombosis (blood clots). The two companies have a long-standing collaboration, which now reaches a total of 12 therapeutic antibodies brought into the clinic – a really impressive number!

This well-known German Biotech is therefore also receiving a milestone payment from Novartis. Although the financial details were not disclosed, with 12 candidates we guess the overall deal must be massive. All antibodies in the collaboration come from HuCAL, MorphoSys’ really successful antibody library.

This is good news, particularly after the recent Phase II/III failure in one of the partnership’s candidates.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

You might also be interested in the following:

Support Us

Become a Member